Trial Profile
Open-label Phase II Trial of Adjuvant bishRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Acronyms FANG Ovarian
- Sponsors Gradalis
- 28 Feb 2023 Status changed from active, no longer recruiting to completed.
- 09 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Jun 2023.
- 09 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2023.